Cargando…
Oral available agents in the treatment of RRMS
Autor principal: | Aupérin, Thierry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3815004/ https://www.ncbi.nlm.nih.gov/pubmed/24194647 http://dx.doi.org/10.2147/DHPS.S54402 |
Ejemplares similares
-
Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS
por: Ziemssen, Tjalf, et al.
Publicado: (2017) -
Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS
por: Ghezzi, Angelo, et al.
Publicado: (2019) -
Th17 cells increase in RRMS as well as in SPMS, whereas various other phenotypes of Th17 increase in RRMS only
por: Kalra, S, et al.
Publicado: (2020) -
Distinct binding properties of TIAR RRMs and linker region
por: Kim, Henry S., et al.
Publicado: (2013) -
Availability of Specific Direct Oral Anticoagulant Reversal Agents in US Hospitals
por: Kanjee, Zahir, et al.
Publicado: (2021)